Evidence map›Paper›PMID 39292641›Full record

ArticleMolecular pharmaceutics2024

Amorphous Solid Dispersion Formation for Enhanced Release Performance of Racemic and Enantiopure Praziquantel.

Hector Polyzois, Hanh Thuy Nguyen, Benedito Roberto de Alvarenga Junior, Lynne S Taylor

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular pharmaceutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Hector PolyzoisDepartment of Industrial and Molecular Pharmaceutics, College of Pharmacy, Purdue University, West Lafayette, Indiana 47907, United States.
Hanh Thuy NguyenDepartment of Industrial and Molecular Pharmaceutics, College of Pharmacy, Purdue University, West Lafayette, Indiana 47907, United States.
Benedito Roberto de Alvarenga JuniorDepartment of Industrial and Molecular Pharmaceutics, College of Pharmacy, Purdue University, West Lafayette, Indiana 47907, United States.
Lynne S TaylorDepartment of Industrial and Molecular Pharmaceutics, College of Pharmacy, Purdue University, West Lafayette, Indiana 47907, United States.ORCID 0000-0002-4568-6021

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Praziquantel (PZQ) is the treatment of choice for schistosomiasis, which affects more than 250 million people globally. Commercial tablets contain the crystalline racemic compound (

Indexed as

CrystallizationDrug LiberationHypromellose DerivativesMethylcellulosePraziquantelSolubilityBiological AvailabilityChemistry, PharmaceuticalDrug CompoundingHot Melt Extrusion TechnologyPolymersStereoisomerismTabletsX-Ray Diffractionhydroxypropylmethylcellulose acetate succinateHypromellose DerivativesMethylcellulosePolymersPraziquantelTabletsamorphous solid dispersionschiralitydrug releasepharmaceutical polymerspraziquantel

Identifiers

PMID39292641
PMCPMC11462518

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.